Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Circulating Tumor DNA Profiling in Small Cell Lung Cancer Identifies Potentially Targetable Alterations.

Devarakonda S, Sankararaman S, Herzog B, Gold KA, Waqar SN, Ward JP, Raymond VM, Lanman RB, Chaudhuri AA, Owonikoko TK, Li BT, Poirier JT, Rudin CM, Govindan R, Morgensztern D.

Clin Cancer Res. 2019 Jul 12. pii: clincanres.0879.2019. doi: 10.1158/1078-0432.CCR-19-0879. [Epub ahead of print]

PMID:
31300452
2.

RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer.

Morgensztern D, Rose M, Waqar SN, Morris J, Ma PC, Reid T, Brzezniak CE, Zeman KG, Padmanabhan A, Hirth J, I Spira A, Trepel JB, Padda SK.

Br J Cancer. 2019 Jun 24. doi: 10.1038/s41416-019-0504-8. [Epub ahead of print]

PMID:
31231122
3.

A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma.

van Brummelen EMJ, Levchenko E, Dómine M, Fennell DA, Kindler HL, Viteri S, Gadgeel S, López PG, Kostorov V, Morgensztern D, Orlov S, Zauderer MG, Vansteenkiste JF, Baker-Neblett K, Vasquez J, Wang X, Bellovin DI, Schellens JHM, Yan L, Mitrica I, DeYoung MP, Trigo J.

Invest New Drugs. 2019 May 7. doi: 10.1007/s10637-019-00783-7. [Epub ahead of print]

PMID:
31065954
4.

Association between depth of response and survival in patients with advanced-stage non-small cell lung cancer treated with first-line chemotherapy.

Morgensztern D, Ko A, O'Brien M, Ong TJ, Waqar SN, Socinski MA, Postmus PE, Bhore R.

Cancer. 2019 Jul 15;125(14):2394-2399. doi: 10.1002/cncr.32114. Epub 2019 Apr 1.

PMID:
30933354
5.

Role of immune checkpoint blockers in patients with EGFR mutation.

Ward J, Morgensztern D.

Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S385-S387. doi: 10.21037/tlcr.2018.09.13. No abstract available.

6.

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.

Drilon A, Fu S, Patel MR, Fakih M, Wang D, Olszanski AJ, Morgensztern D, Liu SV, Cho BC, Bazhenova L, Rodriguez CP, Doebele RC, Wozniak A, Reckamp KL, Seery T, Nikolinakos P, Hu Z, Oliver JW, Trone D, McArthur K, Patel R, Multani PS, Ahn MJ.

Cancer Discov. 2019 Mar;9(3):384-395. doi: 10.1158/2159-8290.CD-18-0839. Epub 2018 Nov 28.

PMID:
30487236
7.

Lorlatinib: a new-generation drug for ALK-positive NSCLC.

Waqar SN, Morgensztern D.

Lancet Oncol. 2018 Dec;19(12):1555-1557. doi: 10.1016/S1470-2045(18)30789-7. Epub 2018 Nov 6. No abstract available.

PMID:
30413381
8.

ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).

Morgensztern D, Cobo M, Ponce Aix S, Postmus PE, Lewanski CR, Bennouna J, Fischer JR, Juan-Vidal O, Stewart DJ, Fasola G, Ardizzoni A, Bhore R, Wolfsteiner M, Talbot DC, Jin Ong T, Govindan R, On Behalf Of The Abound L Investigators.

Cancer. 2018 Dec 15;124(24):4667-4675. doi: 10.1002/cncr.31779. Epub 2018 Nov 1.

PMID:
30383906
9.

NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018.

Kalemkerian GP, Loo BW, Akerley W, Attia A, Bassetti M, Boumber Y, Decker R, Dobelbower MC, Dowlati A, Downey RJ, Florsheim C, Ganti AKP, Grecula JC, Gubens MA, Hann CL, Hayman JA, Heist RS, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran CA, Morgensztern D, Pokharel S, Portnoy DC, Rhodes D, Rusthoven C, Santana-Davila R, Williams CC, Hoffmann KG, Hughes M.

J Natl Compr Canc Netw. 2018 Oct;16(10):1171-1182. doi: 10.6004/jnccn.2018.0079.

PMID:
30323087
10.

First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.

Strickler JH, Weekes CD, Nemunaitis J, Ramanathan RK, Heist RS, Morgensztern D, Angevin E, Bauer TM, Yue H, Motwani M, Parikh A, Reilly EB, Afar D, Naumovski L, Kelly K.

J Clin Oncol. 2018 Nov 20;36(33):3298-3306. doi: 10.1200/JCO.2018.78.7697. Epub 2018 Oct 4. Erratum in: J Clin Oncol. 2019 Jan 20;37(3):261.

PMID:
30285518
11.

Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer.

Wagner AH, Devarakonda S, Skidmore ZL, Krysiak K, Ramu A, Trani L, Kunisaki J, Masood A, Waqar SN, Spies NC, Morgensztern D, Waligorski J, Ponce J, Fulton RS, Maggi LB Jr, Weber JD, Watson MA, O'Conor CJ, Ritter JH, Olsen RR, Cheng H, Mukhopadhyay A, Can I, Cessna MH, Oliver TG, Mardis ER, Wilson RK, Griffith M, Griffith OL, Govindan R.

Nat Commun. 2018 Sep 17;9(1):3787. doi: 10.1038/s41467-018-06162-9.

12.

Non-small-cell Lung Cancer With Brain Metastasis at Presentation.

Waqar SN, Samson PP, Robinson CG, Bradley J, Devarakonda S, Du L, Govindan R, Gao F, Puri V, Morgensztern D.

Clin Lung Cancer. 2018 Jul;19(4):e373-e379. doi: 10.1016/j.cllc.2018.01.007. Epub 2018 Mar 9.

PMID:
29526531
13.

Early Mortality in Patients Undergoing Adjuvant Chemotherapy for Non-Small Cell Lung Cancer.

Morgensztern D, Samson PS, Waqar SN, Devarakonda S, Robinson CG, Govindan R, Puri V.

J Thorac Oncol. 2018 Apr;13(4):543-549. doi: 10.1016/j.jtho.2018.01.010. Epub 2018 Feb 2.

14.

The biology and management of non-small cell lung cancer.

Herbst RS, Morgensztern D, Boshoff C.

Nature. 2018 Jan 24;553(7689):446-454. doi: 10.1038/nature25183. Review.

PMID:
29364287
15.

Percutaneous Image-Guided Ablation in the Treatment of Osseous Metastases from Non-small Cell Lung Cancer.

Ma Y, Wallace AN, Waqar SN, Morgensztern D, Madaelil TP, Tomasian A, Jennings JW.

Cardiovasc Intervent Radiol. 2018 May;41(5):726-733. doi: 10.1007/s00270-017-1843-6. Epub 2017 Dec 4.

PMID:
29204695
16.

nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy.

Thomas M, Spigel DR, Jotte RM, McCleod M, Socinski MA, Page RD, Gressot L, Knoble J, Juan O, Morgensztern D, Isla D, Kim ES, West H, Ko A, Ong TJ, Trunova N, Gridelli C.

Lung Cancer (Auckl). 2017 Oct 30;8:207-216. doi: 10.2147/LCTT.S138570. eCollection 2017.

17.

Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas.

Oronsky B, Ma PC, Morgensztern D, Carter CA.

Neoplasia. 2017 Dec;19(12):991-1002. doi: 10.1016/j.neo.2017.09.002. Epub 2017 Nov 5. Review.

18.

Treatment advances in small cell lung cancer (SCLC).

Waqar SN, Morgensztern D.

Pharmacol Ther. 2017 Dec;180:16-23. doi: 10.1016/j.pharmthera.2017.06.002. Epub 2017 Jun 1. Review.

PMID:
28579387
19.

Adjuvant Chemotherapy Is Associated With Improved Survival in Locally Invasive Node Negative Non-Small Cell Lung Cancer.

Ahmad U, Crabtree TD, Patel AP, Morgensztern D, Robinson CG, Krupnick AS, Kreisel D, Jones DR, Patterson GA, Meyers BF, Puri V.

Ann Thorac Surg. 2017 Jul;104(1):303-307. doi: 10.1016/j.athoracsur.2017.01.069. Epub 2017 Apr 19.

20.

Defining the Ideal Time Interval Between Planned Induction Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer.

Samson P, Crabtree TD, Robinson CG, Morgensztern D, Broderick S, Krupnick AS, Kreisel D, Patterson GA, Meyers B, Puri V.

Ann Thorac Surg. 2017 Apr;103(4):1070-1075. doi: 10.1016/j.athoracsur.2016.09.053. Epub 2017 Jan 19.

21.

Precision medicine in lung cancer: the battle continues.

Waqar SN, Morgensztern D.

J Thorac Dis. 2016 Nov;8(11):2991-2993. doi: 10.21037/jtd.2016.11.46. No abstract available.

22.

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.

Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA 3rd, Robert F, Han TH, Bheddah S, Theiss N, Watson S, Mathur D, Vennapusa B, Zayed H, Lally S, Strickland DK, Govindan R, Dylla SJ, Peng SL, Spigel DR; SCRX16-001 investigators.

Lancet Oncol. 2017 Jan;18(1):42-51. doi: 10.1016/S1470-2045(16)30565-4. Epub 2016 Dec 5.

23.

Evolving Treatment Options for Lung Cancer.

Morgensztern D, Herbst RS.

Hematol Oncol Clin North Am. 2017 Feb;31(1):xiii-xiv. doi: 10.1016/j.hoc.2016.09.001. No abstract available.

PMID:
27912837
24.

Systemic Treatment of Brain Metastases.

Waqar SN, Morgensztern D, Govindan R.

Hematol Oncol Clin North Am. 2017 Feb;31(1):157-176. doi: 10.1016/j.hoc.2016.08.007. Review.

PMID:
27912831
25.

Immunotherapy in Lung Cancer.

Du L, Herbst RS, Morgensztern D.

Hematol Oncol Clin North Am. 2017 Feb;31(1):131-141. doi: 10.1016/j.hoc.2016.08.004. Review.

PMID:
27912829
26.

Immune checkpoint inhibition in patients with brain metastases.

Johanns T, Waqar SN, Morgensztern D.

Ann Transl Med. 2016 Oct;4(Suppl 1):S9. No abstract available.

27.

Role for adjuvant chemotherapy in patients with resected small cell lung cancer.

Du L, Waqar SN, Morgensztern D.

J Thorac Dis. 2016 Aug;8(8):1891-2. doi: 10.21037/jtd.2016.07.15. No abstract available.

28.

Multimodality Therapy for NSCLC.

Du L, Waqar SN, Morgensztern D.

Cancer Treat Res. 2016;170:151-63. doi: 10.1007/978-3-319-40389-2_7. Review.

PMID:
27535393
29.

Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC.

Morgensztern D, Du L, Waqar SN, Patel A, Samson P, Devarakonda S, Gao F, Robinson CG, Bradley J, Baggstrom M, Masood A, Govindan R, Puri V.

J Thorac Oncol. 2016 Oct;11(10):1729-35. doi: 10.1016/j.jtho.2016.05.022. Epub 2016 Jun 8.

30.

Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer.

Morgensztern D, Herbst RS.

Clin Cancer Res. 2016 Aug 1;22(15):3713-7. doi: 10.1158/1078-0432.CCR-15-2998. Epub 2016 Jun 1. Review.

31.

Patterns of care in hilar node-positive (N1) non-small cell lung cancer: A missed treatment opportunity?

Bott MJ, Patel AP, Verma V, Crabtree TD, Morgensztern D, Robinson CG, Colditz GA, Waqar S, Kreisel D, Krupnick AS, Patterson GA, Broderick S, Meyers BF, Puri V.

J Thorac Cardiovasc Surg. 2016 Jun;151(6):1549-1558.e2. doi: 10.1016/j.jtcvs.2016.01.058. Epub 2016 Mar 12.

32.

Delayed nausea and vomiting from carboplatin doublet chemotherapy.

Waqar SN, Mann J, Baggstrom MQ, Waqar MA, Chitneni P, Williams K, Gao F, Morgensztern D, Govindan R.

Acta Oncol. 2016 Jun;55(6):700-4. doi: 10.3109/0284186X.2016.1154603. Epub 2016 May 4.

33.

A Phase I Trial of Temsirolimus and Pemetrexed in Patients with Advanced Non-Small Cell Lung Cancer.

Waqar SN, Baggstrom MQ, Morgensztern D, Williams K, Rigden C, Govindan R.

Chemotherapy. 2016;61(3):144-7. doi: 10.1159/000442147. Epub 2016 Jan 19.

34.

Immunogenicity of Influenza Vaccination in Patients With Cancer.

Waqar SN, Boehmer L, Morgensztern D, Wang-Gillam A, Sorscher S, Lawrence S, Gao F, Guebert K, Williams K, Govindan R.

Am J Clin Oncol. 2018 Mar;41(3):248-253. doi: 10.1097/COC.0000000000000257.

35.

Response to "Is post-operative radiotherapy of any benefit after R0 resection for N2 disease?".

Robinson CG, Patel AP, DeWees T, Morgensztern D, Bradley JD, Puri V.

Transl Lung Cancer Res. 2015 Oct;4(5):667. doi: 10.3978/j.issn.2218-6751.2015.08.12. No abstract available.

36.

Chemotherapy for Advanced-Stage Non-Small Cell Lung Cancer.

Du L, Morgensztern D.

Cancer J. 2015 Sep-Oct;21(5):366-70. doi: 10.1097/PPO.0000000000000141. Review.

PMID:
26389760
37.

Brain Metastases at Presentation in Patients With Non-Small Cell Lung Cancer.

Waqar SN, Waqar SH, Trinkaus K, Gadea CA, Robinson CG, Bradley J, Watson MA, Puri V, Govindan R, Morgensztern D.

Am J Clin Oncol. 2018 Jan;41(1):36-40. doi: 10.1097/COC.0000000000000230.

38.

Treatment Outcomes in Stage I Lung Cancer: A Comparison of Surgery and Stereotactic Body Radiation Therapy.

Puri V, Crabtree TD, Bell JM, Broderick SR, Morgensztern D, Colditz GA, Kreisel D, Krupnick AS, Patterson GA, Meyers BF, Patel A, Robinson CG.

J Thorac Oncol. 2015 Dec;10(12):1776-84. doi: 10.1097/JTO.0000000000000680.

39.

The Role of Surgical Resection in Stage IIIA Non-Small Cell Lung Cancer: A Decision and Cost-Effectiveness Analysis.

Samson P, Patel A, Robinson CG, Morgensztern D, Chang SH, Colditz GA, Waqar S, Crabtree TD, Krupnick AS, Kreisel D, Patterson GA, Meyers BF, Puri V.

Ann Thorac Surg. 2015 Dec;100(6):2026-32; discussion 2032. doi: 10.1016/j.athoracsur.2015.05.091. Epub 2015 Aug 25.

40.

Multidisciplinary Treatment for Stage IIIA Non-Small Cell Lung Cancer: Does Institution Type Matter?

Samson P, Patel A, Crabtree TD, Morgensztern D, Robinson CG, Colditz GA, Waqar S, Kreisel D, Krupnick AS, Patterson GA, Broderick S, Meyers BF, Puri V.

Ann Thorac Surg. 2015 Nov;100(5):1773-9. doi: 10.1016/j.athoracsur.2015.04.144. Epub 2015 Jul 28.

41.

Reply to C. Le Péchoux et al and B.S. Gill et al.

Robinson CG, Patel AP, DeWees T, Morgensztern D, Bradley JD, Puri V.

J Clin Oncol. 2015 Sep 10;33(26):2932-3. doi: 10.1200/JCO.2015.62.5731. Epub 2015 Jul 27. No abstract available.

PMID:
26215956
42.

EGFR Mutations in Non-Small-Cell Lung Cancer: Find, Divide, and Conquer.

Morgensztern D, Politi K, Herbst RS.

JAMA Oncol. 2015 May;1(2):146-8. doi: 10.1001/jamaoncol.2014.278. No abstract available.

PMID:
26181013
43.

Genomic alterations in lung adenocarcinoma.

Devarakonda S, Morgensztern D, Govindan R.

Lancet Oncol. 2015 Jul;16(7):e342-51. doi: 10.1016/S1470-2045(15)00077-7. Review.

PMID:
26149886
44.

Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era?

Waqar SN, Morgensztern D.

Expert Rev Clin Immunol. 2015;11(8):871-3. doi: 10.1586/1744666X.2015.1054374. Epub 2015 Jun 7. Review.

PMID:
26051156
45.

Role for Surgical Resection in the Multidisciplinary Treatment of Stage IIIB Non-Small Cell Lung Cancer.

Bott MJ, Patel AP, Crabtree TD, Morgensztern D, Robinson CG, Colditz GA, Waqar S, Kreisel D, Krupnicka AS, Patterson GA, Broderick S, Meyers BF, Puri V.

Ann Thorac Surg. 2015 Jun;99(6):1921-8. doi: 10.1016/j.athoracsur.2015.02.033. Epub 2015 Apr 23.

46.

MET Mutation Associated with Responsiveness to Crizotinib.

Waqar SN, Morgensztern D, Sehn J.

J Thorac Oncol. 2015 May;10(5):e29-31. doi: 10.1097/JTO.0000000000000478. No abstract available.

47.

Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base.

Robinson CG, Patel AP, Bradley JD, DeWees T, Waqar SN, Morgensztern D, Baggstrom MQ, Govindan R, Bell JM, Guthrie TJ, Colditz GA, Crabtree TD, Kreisel D, Krupnick AS, Patterson GA, Meyers BF, Puri V.

J Clin Oncol. 2015 Mar 10;33(8):870-6. doi: 10.1200/JCO.2014.58.5380. Epub 2015 Feb 9.

48.

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R.

J Thorac Oncol. 2015 Jan;10(1 Suppl 1):S1-63. doi: 10.1097/JTO.0000000000000405.

49.

US breast cancer mortality trends in young women according to race.

Ademuyiwa FO, Gao F, Hao L, Morgensztern D, Aft RL, Ma CX, Ellis MJ.

Cancer. 2015 May 1;121(9):1469-76. doi: 10.1002/cncr.29178. Epub 2014 Dec 5.

50.

Clinical next-generation sequencing in patients with non-small cell lung cancer.

Hagemann IS, Devarakonda S, Lockwood CM, Spencer DH, Guebert K, Bredemeyer AJ, Al-Kateb H, Nguyen TT, Duncavage EJ, Cottrell CE, Kulkarni S, Nagarajan R, Seibert K, Baggstrom M, Waqar SN, Pfeifer JD, Morgensztern D, Govindan R.

Cancer. 2015 Feb 15;121(4):631-9. doi: 10.1002/cncr.29089. Epub 2014 Oct 24.

Supplemental Content

Loading ...
Support Center